Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Infect Genet Evol ; 54: 183-191, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28688977

RESUMEN

BACKGROUND: The prevalence of HIV-1 drug resistance among treatment-naïve patients ranges between 8.3% and 15% in Europe and North America. Previous studies showed that subtypes A and B were the most prevalent in the Greek HIV-1 epidemic. Our aim was to estimate the prevalence of resistance among drug naïve patients in Greece and to investigate the levels of transmission networking among those carrying resistant strains. METHODS: HIV-1 sequences were determined from 3428 drug naïve HIV-1 patients, in Greece sampled during 01/01/2003-30/6/2015. Transmission clusters were estimated by means of phylogenetic analysis including as references sequences from patients failing antiretroviral treatment in Greece and sequences sampled globally. RESULTS: The proportion of sequences with SDRMs was 5.98% (n=205). The most prevalent SDRMs were found for NNRTIs (3.76%), followed by N(t)RTIs (2.28%) and PIs (1.02%). The resistance prevalence was 22.2% based on all mutations associated with resistance estimated using the HIVdb resistance interpretation algorithm. Resistance to NNRTIs was the most common (16.9%) followed by PIs (4.9%) and N(t)RTIs (2.8%). The most frequently observed NNRTI resistant mutations were E138A (7.7%), E138Q (4.0%), K103N (2.3%) and V179D (1.3%). The majority of subtype A sequences (89.7%; 245 out of 273) with the dominant NNRTI resistance mutations (E138A, K103N, E138Q, V179D) were found to belong to monophyletic clusters suggesting regional dispersal. For subtype B, 68.1% (139 out of 204) of resistant strains (E138A, K103N, E138Q V179D) belonged to clusters. For N(t)RTI-resistance, evidence for regional dispersal was found for 27.3% and 21.6% of subtype A and B sequences, respectively. CONCLUSIONS: The TDR rate based on the prevalence of SDRM is lower than the average rate in Europe. However, the prevalence of NNRTI resistance estimated using the HIVdb approach, is high in Greece and it is mostly due to onward transmissions among drug-naïve patients.


Asunto(s)
Farmacorresistencia Viral , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/uso terapéutico , Femenino , Genotipo , Grecia/epidemiología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/transmisión , VIH-1/clasificación , VIH-1/genética , Humanos , Masculino , Mutación , Filogenia , Prevalencia
2.
Transplant Proc ; 46(9): 3191-3, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25420856

RESUMEN

INTRODUCTION: Bacteremias among renal transplant recipients are more frequent as a result of immunosuppression. They are considered extremely high-risk because they are correlated with decreased allograft and recipient survival. PATIENTS AND METHODS: All episodes of bacteremia among renal transplant recipients were documented following review of medical records, from January 2010 to May 2013. RESULTS: In total 26 episodes of bacteremia were observed in 22 patients. Gram negative bacteremia was identified in 73% (19/26) cases. Pathogens according to their frequency were the following Escherichia coli (6/26, 23%), Klebsiella pneumonia (5/26, 19%), Pseudomonas aeruginosa (3/26, 11%), Staphylococcus epidermidis (3/26, 11%), Acinetobacter baumanni (2/26, 7.7%), Enterococcus faecalis (2/26, 7.7%). The first trimester post renal transplantation 18 episodes (69%) of bacteremia were presented that were not correlated to indwelling urinary catheter or stent. Positive urinary culture with the same pathogen was recognized in 13 patients. All recipients manifested fever, eight recipients had leucocytosis and three cases were complicated by septic shock. Immediate resuscitation with intravenous fluids and non-nephrotoxic antibiotic regimen was initiated. Acute renal allograft dysfunction (defined as an increase in serum creatinine more than 0.5 mg/dL from baseline) was observed in five patients and was restored following infection resolution. CONCLUSION: Increased prevalence of bacteremia in renal transplant recipients is attributed to immunosuppression and usually bacteremic episodes follow urinary tract infection. The commonest pathogens are Gram negative bacteria with E. coli the most frequent. Early detection and proper management are important as bacteremia affects renal allograft and recipient survival.


Asunto(s)
Bacteriemia/epidemiología , Bacterias Gramnegativas/aislamiento & purificación , Trasplante de Riñón , Receptores de Trasplantes , Adulto , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Adulto Joven
3.
Transpl Infect Dis ; 16(3): 461-4, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24750300

RESUMEN

We present a unique case of acute bacterial prostatitis caused by a very rare human pathogen, Raoultella planticola, in a renal allograft recipient 3.5 months post transplantation. Only a few cases of human infection by this pathogen have been reported worldwide. The present study reports the case of a 67-year-old man who was admitted to our transplant unit 3.5 months post transplantation with fever, dysuria, suprapubic pain, symptoms and signs of acute prostatitis, and elevated markers of inflammation and prostate-specific antigen. R. planticola was isolated in the urine culture. The patient was treated with ciprofloxacin (based on the antibiogram) and had a full recovery, with satisfactory renal function. To the best of our knowledge, this is not only the first reported case of R. planticola prostatitis, but also the first report of such an infection in a solid organ transplant recipient or in a patient on immunosuppressive medication.


Asunto(s)
Bacterias Aerobias Gramnegativas/clasificación , Infecciones por Bacterias Gramnegativas/microbiología , Trasplante de Riñón , Prostatitis/microbiología , Anciano , Antibacterianos/uso terapéutico , Ciprofloxacina/uso terapéutico , Humanos , Masculino , Prostatitis/tratamiento farmacológico
4.
Eur J Clin Microbiol Infect Dis ; 29(9): 1095-101, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20703891

RESUMEN

Staphylococcus aureus (SA) bacteriuria may accompany SA bacteremia, but primary SA urinary tract infection (UTI) may also occur. Our clinical observation of SA UTIs following intravenous catheter-related phlebitis lead us to review hematogenous and ascending route-related risk factors in patients with primary SA UTIs. The charts from all patients with SA UTIs over a 1.5-year period were reviewed for concurrent or recent hospitalization, intravenous catheterization, and for known UTI risk factors. Patients with concurrent SA bacteremia were excluded. Patients with Escherichia coli UTIs during the same period were included as controls. Twenty cases of primary SA UTI were compared with 43 E. coli UTI cases and they did not differ in age, diabetes mellitus, prostatic hypertrophy, previous UTI, or other urinary tract (UT) abnormality. However, cases were more likely than controls to have had recent or concurrent hospitalization, UT catheterization, and history of recent phlebitis. In multivariate analysis, UT catheterization and recent hospitalization retained significant association with SA UTI. Similar results were shown for the methicillin-resistant SA UTI subgroup. Even though UT catheterization is the main predisposing factor for primary SA UTI, some cases may be mediated through unrecognized preceding bacteremia related to intravascular device exposure or other healthcare-related factors.


Asunto(s)
Bacteriemia/complicaciones , Bacteriemia/epidemiología , Infecciones Estafilocócicas/epidemiología , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/aislamiento & purificación , Infecciones Urinarias/epidemiología , Infecciones Urinarias/microbiología , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Cateterismo/efectos adversos , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Flebitis/complicaciones , Factores de Riesgo , Estados Unidos/epidemiología
5.
Int J STD AIDS ; 21(2): 147-8, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20090004

RESUMEN

We report an extreme case of high-grade needlestick exposure of a health-care worker to serum from multiple HIV-infected patients after trying to prematurely remove the respective tubes from an automated biochemical analyser. After review of the medical records of the eight source patients, we offered the health-care worker an expanded postexposure prophylaxis regimen including the entry inhibitor enfuvirtide. She refused to take subcutaneous injections, so we recommended the use of the integrase inhibitor raltegravir. She completed therapy without problems and periodic evaluation for HIV transmission up to nine months after the incident was negative.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Dedos , Infecciones por VIH/prevención & control , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Lesiones por Pinchazo de Aguja , Enfermedades Profesionales/prevención & control , Profilaxis Posexposición/métodos , Adenina/administración & dosificación , Adenina/análogos & derivados , Terapia Antirretroviral Altamente Activa , Darunavir , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Emtricitabina , Enfuvirtida , Femenino , Proteína gp41 de Envoltorio del VIH/administración & dosificación , Humanos , Persona de Mediana Edad , Enfermedades Profesionales/virología , Organofosfonatos/administración & dosificación , Fragmentos de Péptidos/administración & dosificación , Ritonavir/administración & dosificación , Sulfonamidas/administración & dosificación , Tenofovir
7.
Int J STD AIDS ; 19(8): 570-2, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18663051

RESUMEN

Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, mainly met in severely immunocompromised, HIV-positive patients. PEL is aetiologically related to human herpes virus-8 (HHV-8) and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumour mass. Recently, cases of HIV-positive patients with HHV-8-positive solid tissue lymphomas, not associated with an effusion, have been reported (solid variant of PEL). The prognosis of PEL is reported to be poor. We report a case of an HIV-positive patient with a typical solid variant of PEL without effusion. Interestingly, his disease developed while being on stable antiretroviral therapy (ART) with high CD4 counts. He had a relatively long survival with chemotherapy and ART.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Herpesvirus Humano 8 , Linfoma Relacionado con SIDA/patología , Linfoma de Efusión Primaria/patología , Adulto , Infecciones por VIH/complicaciones , Infecciones por VIH/inmunología , VIH-1/efectos de los fármacos , Humanos , Linfoma Relacionado con SIDA/virología , Linfoma de Efusión Primaria/virología , Masculino , Resultado del Tratamiento
8.
Clin Microbiol Infect ; 7(1): 3-10, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11284936

RESUMEN

OBJECTIVE: To determine the specific characteristics of Streptococcus bovis infective endocarditis (IE) by reviewing our own experience of S. bovis IE. METHODS: Twenty episodes of definite S. bovis IE were reviewed in 20 patients hospitalized from 1980 to 1996. RESULTS: The mean age was 62 +/- 14 years, and 14 (70%) patients had no known predisposing cardiac condition. The principal antimicrobials used were penicillin G (N = 10) and amoxycillin (N = 8). Surgery was required in four (20%) patients. Neurologic complications occurred in eight (40%) patients, after initiation of therapy in six (75%) (mean time: 14 days). An unfavorable outcome was observed in four of 20 patients and tended to be more frequent in patients who had had neurologic complications (P = 0.10). Colonic tumors were present in 11 of 16 (69%) patients. CONCLUSIONS: Advanced age, occurrence of IE on presumably normal valves, high rate of neurologic complications, associated gastrointestinal diseases and low mortality rate during initial follow-up are characteristic features of S. bovis IE observed in this study.


Asunto(s)
Endocarditis Bacteriana , Infecciones Estreptocócicas , Streptococcus bovis , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Ecocardiografía , Endocarditis Bacteriana/complicaciones , Endocarditis Bacteriana/tratamiento farmacológico , Endocarditis Bacteriana/microbiología , Endocarditis Bacteriana/mortalidad , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Infecciones Estreptocócicas/complicaciones , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/mortalidad , Streptococcus bovis/efectos de los fármacos , Streptococcus bovis/aislamiento & purificación
9.
J Chemother ; 12(3): 258-60, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10877523

RESUMEN

The case of an AIDS patient with cytomegalovirus (CMV) retinitis who was treated with cidofovir for 17 consecutive months, without any adverse effect, is presented. In the context of antiretroviral therapy, cidofovir therapeutic regimen was 5 mg/kg of body weight for 2 weeks and 5 mg/kg thereafter every other week. Probenecid, hydration and monitoring for proteinuria were also used to prevent nephrotoxicity. The patient stopped maintenance therapy for CMV retinitis after the permanent rise of CD4+ cells above 100 c/mm3. For more than 10 months after drug withdrawal the patient remains free of retinitis.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antivirales/uso terapéutico , Retinitis por Citomegalovirus/tratamiento farmacológico , Citosina/análogos & derivados , Citosina/uso terapéutico , Organofosfonatos , Compuestos Organofosforados/uso terapéutico , Adulto , Cidofovir , Citomegalovirus/crecimiento & desarrollo , Esquema de Medicación , Humanos , Masculino , Activación Viral/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...